APA (7th ed.) Citation

EM, S., P, R., J, M., JD, B., BM, U., G, C., & MW, K. (2022). The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. Multiple sclerosis (Houndmills, Basingstoke, England), 28(10), 1606. https://doi.org/10.1177/13524585221105465

Chicago Style (17th ed.) Citation

EM, Strijbis, Repovic P, Mostert J, Bowen JD, Uitdehaag BM, Cutter G, and Koch MW. "The MSIS-29 and SF-36 as Outcomes in Secondary Progressive MS Trials." Multiple Sclerosis (Houndmills, Basingstoke, England) 28, no. 10 (2022): 1606. https://doi.org/10.1177/13524585221105465.

MLA (9th ed.) Citation

EM, Strijbis, et al. "The MSIS-29 and SF-36 as Outcomes in Secondary Progressive MS Trials." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 28, no. 10, 2022, p. 1606, https://doi.org/10.1177/13524585221105465.